Genetic Engineering

Frustrated cancer researchers: Who owns our mice?

Published in Cancer Weekly, November 25th, 2003

Each year, millions of mice are genetically engineered to precisely mimic human cancers - a technology that could lead to the swift development of new and targeted treatments.

But many researchers complain that progress is being slowed by commerce. That's because E.I. duPont de Nemours and Co. lays broad intellectual property claims to drug discoveries made with just about any animal genetically engineered to be prone to just about any cancer.

duPont and Harvard claim the terms are typical of such arrangements between industry and academia and aren't particularly onerous. But many researchers and other university patent officials allege that DuPont...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry